TAK-881

Phase 3Biologic

TAK-881 is one of 25 biologic programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyradiculoneuropathyActive, not recruiting

Immunodeficiency DiseaseActive, not recruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 3

Active, not recruiting

Immunodeficiency DiseasePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Immunodeficiency Disease

#DrugCompanyPhaseTrials

Famvir

Retrovir

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—4

Epivir

GGlaxo Dba Glaxosmithkline

Asceniv

1 6

HYQVIA

Takeda

Phase 3

1 7

TAK-771

Takeda

Phase 3

2 8

Newgam

Octapharma

Phase 3

1 9

TAK-881

Takeda

Phase 3

3 10

Octanorm

Octapharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06747351

Q1 2029

Phase 3Recruiting

Immunodeficiency Disease

NCT06076642

Clinical

Trials by Indication[1]

Immunodeficiency Disease3 trials

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Completed· Takeda logo

Takeda·Phase 2/3·NCT05755035·65 enrolled

Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA

Available· Takeda logo

Takeda··NCT06955793

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Recruiting· Takeda logo

Takeda·Phase 3·NCT06076642·39 enrolled

Adult3 trials

A Study of TAK-881 in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT05059977·24 enrolled

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06935266·64 enrolled

A Study of TAK-881 and HyQvia in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06895967·30 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting· Takeda logo

Takeda·Phase 3·NCT06747351·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for TAK-881. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-881 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-881. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Takeda

TAK-881

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

Immunodeficiency Disease3 trials

Adult3 trials

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

References

Drug Info

Quick Facts

Related News